Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:BFRINASDAQ:MYNZNASDAQ:ZVSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$7.76+2.1%$7.53$6.51▼$17.05$8.23M1.692,520 shs2,511 shsBFRIBiofrontera$0.81-2.4%$0.89$0.65▼$2.22$7.18M0.36912,016 shs19,973 shsMYNZMainz Biomed$3.53+10.3%$4.22$2.65▼$43.20$8.19M0.53103,175 shs237,378 shsZVSAZyVersa Therapeutics$0.70-2.0%$0.87$0.55▼$6.70$1.80M0.691.14 million shs71,714 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+3.82%-1.29%-4.32%-11.38%-51.73%BFRIBiofrontera+2.09%-2.47%-7.89%-23.94%-50.06%MYNZMainz Biomed+1.59%-0.62%-24.71%-28.09%-91.08%ZVSAZyVersa Therapeutics+1.00%+2.29%-2.31%-51.71%-88.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics1.8472 of 5 stars3.53.00.00.02.40.80.0BFRIBiofrontera2.7909 of 5 stars3.55.00.00.00.00.01.3MYNZMainz Biomed1.6826 of 5 stars3.33.00.00.00.00.81.3ZVSAZyVersa Therapeutics0.9634 of 5 stars0.05.00.00.02.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00286.55% UpsideBFRIBiofrontera 3.00Buy$7.00764.73% UpsideMYNZMainz Biomed 2.50Moderate Buy$14.00296.60% UpsideZVSAZyVersa Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZVSA, BFRI, ADXN, and MYNZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/14/2025MYNZMainz BiomedMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$556.05K14.79N/AN/A$1.20 per share6.47BFRIBiofrontera$37.32M0.19N/AN/A$3.16 per share0.26MYNZMainz Biomed$893.99K9.16N/AN/A$10.82 per share0.33ZVSAZyVersa TherapeuticsN/AN/AN/AN/A$88.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$0.34N/A∞N/A850.30%-112.43%-77.95%4/25/2025 (Estimated)BFRIBiofrontera-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%5/13/2025 (Estimated)MYNZMainz Biomed-$26.30M-$65.60N/AN/AN/AN/AN/AN/A7/1/2025 (Estimated)ZVSAZyVersa Therapeutics-$98.30MN/A0.00N/AN/AN/A-224.85%-103.22%5/13/2025 (Estimated)Latest ZVSA, BFRI, ADXN, and MYNZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025BFRIBiofrontera-$0.14N/AN/AN/AN/AN/A4/25/2025H2 2024ADXNAddex Therapeutics-$1.4197N/AN/AN/A$0.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.594.59BFRIBiofronteraN/A1.530.94MYNZMainz BiomedN/A0.240.19ZVSAZyVersa TherapeuticsN/A0.030.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%BFRIBiofrontera10.08%MYNZMainz BiomedN/AZVSAZyVersa Therapeutics3.91%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%BFRIBiofrontera0.21%MYNZMainz Biomed18.20%ZVSAZyVersa Therapeutics0.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableBFRIBiofrontera708.87 million7.73 millionNo DataMYNZMainz Biomed302.32 million1.64 millionNot OptionableZVSAZyVersa Therapeutics22.57 million2.34 millionNot OptionableZVSA, BFRI, ADXN, and MYNZ HeadlinesRecent News About These CompaniesZyVersa Therapeutics CEO provides update on inflammasome ASC inhibitor IC 100April 25 at 3:54 AM | markets.businessinsider.comZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development StatusApril 24 at 7:57 AM | globenewswire.comShort Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Decreases By 41.6%April 19, 2025 | americanbankingnews.comZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental ...April 10, 2025 | seekingalpha.comWhy ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?April 10, 2025 | msn.comWhy ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?April 10, 2025 | insidermonkey.comZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)April 8, 2025 | globenewswire.comZyVersa Therapeutics files to sell 4.21M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comZyVersa Therapeutics reports FY24 EPS ($8.48) vs. ($1089.70) last yearMarch 28, 2025 | markets.businessinsider.comZyVersa Therapeutics expects cash to fund requirements on month-to-month basisMarch 28, 2025 | markets.businessinsider.comZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | globenewswire.comZyVersa Therapeutics announces publication of data on inflammasome inhibitionMarch 19, 2025 | markets.businessinsider.comZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model StudyMarch 18, 2025 | globenewswire.comZyVersa Therapeutics, Inc. Advances Alzheimer's Treatment Research with Promising Data on Inflammasome ASC Inhibitor IC 100March 12, 2025 | quiverquant.comZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse ModelMarch 12, 2025 | globenewswire.comZyVersa Therapeutics Advances Cardio-Metabolic Treatment With IC 100 In Obese Animal ModelMarch 8, 2025 | nasdaq.comZyVersa Therapeutics prices 2.1M shares at 95c in private placementMarch 6, 2025 | markets.businessinsider.comZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The MarketMarch 6, 2025 | globenewswire.comZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibitionMarch 5, 2025 | markets.businessinsider.comZyVersa Therapeutics Highlights Promising Data for Inflammasome ASC Inhibitor IC 100 in Treating Heart Failure with Preserved Ejection Fraction and Associated Metabolic ConditionsMarch 5, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZVSA, BFRI, ADXN, and MYNZ Company DescriptionsAddex Therapeutics NASDAQ:ADXN$7.76 +0.16 (+2.11%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Biofrontera NASDAQ:BFRI$0.80 -0.02 (-2.90%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Mainz Biomed NASDAQ:MYNZ$3.53 +0.33 (+10.31%) Closing price 04:00 PM EasternExtended Trading$3.50 -0.02 (-0.71%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.ZyVersa Therapeutics NASDAQ:ZVSA$0.70 -0.01 (-1.97%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.00 (+0.57%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
